2014

Global Intravenous Immunoglobulin (IVIg) Industry

NEW YORK, Oct. 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Intravenous Immunoglobulin (IVIg) Industry

http://www.reportlinker.com/p01010170/Global-Intravenous-Immunoglobulin-IVIg-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 26 companies including many key and niche players such as Baxter International Inc., Beijing Tiantan Biological Products Co., Ltd., Bharat Serums and Vaccines Ltd., Biotest AG, China Biologic Products, Inc., CSL Limited, Grifols, S.A, Guizhou Taibang Biological Products Co., Ltd., Huanlan Biological Engineering Inc., Kedrion S.p.A., LFB Group, Octapharma AG, OMRIX Biopharmaceuticals Ltd., Shanghai RAAS Blood Products Co., Ltd., and Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Intravenous Immunoglobulin - A Proliferating Biologic II-1

Recession Fails to Dampen IVIg Sector II-1

Outlook II-1

Clinical Uses of Intravenous Immunoglobulin II-2

Neurology II-2

Hematology II-2

Immunology II-2

Dermatology II-2

Nephrology, Rheumatology, Ophthalmology, and Other Diseases II-2

Competitive Scenario II-2

Table 1: Global IVIg Market (2011): Percentage Breakdown of

Market Share for Leading Players (includes corresponding

Graph/Chart) II-3

Indications Addressed by Major Global IVIg Manufacturers II-3

Immunoglobulins - A Unique and Expensive Therapy Subset II-3

Table 2: Comparative Costs between Plasma Protein Therapies

and Artificially Synthesized Pharmaceuticals (includes

corresponding Graph/Chart) II-4

2. MARKET TRENDS & ISSUES II-5

Increasing Awareness of PID to Drive IVIg Market II-5

Regulations Exercise a Tight Rein over Plasma- Therapy &

Immunoglobulin Landscape II-5

Subcutaneous IVIg Formulations Gain Therapeutic Foothold II-5

Potential Approval of IVIg for Alzheimer's - A Crucial

Breakthrough for Medicine II-6

Plasma Market - IVIg's Promising Parent Witnesses Surging Demand II-6

New Concept to Stimulate Plasma Market: Welsh Blood Service

Proposes Sale of Blood Plasma II-6

China Witnessing Acute Blood Plasma Shortage II-6

Key Statistics II-7

Table 3: Global Blood Market by Region (2011 & 2015):

Percentage Breakdown by Value by Region (includes

corresponding Graph/Chart) II-7

Table 4: Global Plasma (excluding Recombinant Factors)

Products Market (2011): Percentage Breakdown by Product for

IVIg, Factor VIII, Albumin, Hyperimmunes, Factor IX, and

Others (includes corresponding Graph/Chart) II-7

Table 5: Global Plasma Market (2011): Percentage Breakdown

for Leading Players for Baxter, Grifols, CSL Ltd, and Others

(includes corresponding Graph/Chart) II-8

Table 6: Global Market for Plasma Fractions (excluding

Recombinant Factors) Market (2011): Percentage Breakdown of

Value Sales by Region (includes corresponding Graph/Chart) II-8

Table 7: Global Market for IVIg/SCIG (2011): Consumption in

Select Countries (in grams per 1000 Inhabitants) (includes

corresponding Graph/Chart) II-8

Table 8: Global Market for IVIg/SCIG (2012): Percentage

Breakdown of Volume Consumption by Medical Specialty

(includes corresponding Graph/Chart) II-9

IVIg Products Offered by Global Leading Players II-9

3. THERAPY OVERVIEW II-10

Introduction II-10

Intravenous Immunoglobulin II-10

Mechanism of IVIg Action II-10

Plasma Collection II-11

Plasma Fractionation Process II-11

IVIg Dosage II-11

FDA-Approved Applications for IVIg II-12

Common IVIg Intravenous Dosing Recommendations by Indication II-12

Intravenous Immunoglobulin Therapy for IVIg Medically

Indicated Conditions II-13

Primary Immunodeficiency Diseases II-13

Pediatric AIDS II-13

B-Cell Chronic Lymphocytic Leukemia (CLL) II-13

Multiple Myeloma II-13

Allogeneic Stem Cell and Bone Marrow Transplantation II-13

Immune or Idiopathic Thrombocytopenic Purpura (ITP) II-13

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) II-13

Guillain-Barré Syndrome II-13

Multifocal Motor Neuropathy II-14

Kawasaki Disease II-14

Hemolytic Disease of the Newborn II-14

Other PIDs II-14

Secondary Immunosuppression II-14

Post-Transfusion Purpura II-14

Polymyositis II-14

Myasthenia Gravis II-14

Dermatomyositis II-14

Moersch-Woltmann (Stiff-man) Syndrome II-14

Neonatal Alloimmune Thrombocytopenia (NAIT) II-15

Parvovirus II-15

Lambert-Eaton Myasthenic Syndrome II-15

Hyperimmunoglobulinemia E Syndrome II-15

Autoimmune Mucocutaneous Blistering Diseases II-15

Multiple Sclerosis II-15

Systemic lupus Erythematosus (SLE) II-15

IgG Deficiencies II-15

Renal Transplant II-16

Churg-Strauss Syndrome (CSS) II-16

Toxic Shock Syndrome II-16

Other Secondary Immunosuppression II-16

Off-Label Applications for IVIg II-16

Complications and Side Effects II-17

4. REGULATORY APPROVALS II-18

Baxter Obtains FDA Approval for Subcutaneous GAMMAGARD LIQUID II-18

CSL Behring Secures FDA Approval to Increase Shelf Life of

Hizentra II-18

Talecris Biotherapeutics Holdings Obtains FDA Approval for

Gamunex-C II-18

CSL Behring Secures FDA Approval to Increase Shelf Life of

Privigen® II-18

China includes IVIg on Rural Reimbursement List II-19

5. PRODUCT INNOVATIONS/INTRODUCTIONS II-20

Octapharma USA Re-launches octagam® 5% Liquid II-20

Baxter Unveils GAMMAGARD Liquid 10% Solution in 30g Dosage II-20

LFB Biomédicaments Unveils CLAIRYG® Liquid Intravenous

Immunoglobulin II-21

Grifols Introduces Flebogamma® 10%DIF Intravenous Immunoglobulin II-21

Grifols Introduces Niuliva® II-21

6. RECENT INDUSTRY ACTIVITY II-22

Wuhan Institute of Biologic Products and China National

Biotech Group Expand Partnership with ProMetic Life Sciences II-22

Momenta Pharmaceuticals Takes Over Virdante's Assets II-22

Sao Paulo State to Establish Plasma Fractionation Plant II-22

Grifols to Construct Plasma Fractionation Facility in Spain II-22

GE Healthcare and Neste Jacobs Forge Partnership to Promote

Self-Reliance in Plasma Fractionation Globally II-23

ProMetic Life Sciences and Novozymes Enter into Strategic

Alliance II-23

Abraxis BioScience and ProMetic Life Sciences Ink

Collaboration Agreement II-23

Grifols Takes Over Talecris II-24

ProMetic LifeSciences and HemCon Medical Technologies Ink

Collaborative Development Deal II-24

LFB Biotechnologies and Therapure Biopharma Ink Development

Services Contract II-25

Biotest Pharmaceuticals Takes Over Plasmapheresis Centre II-25

GE Healthcare and Celestial Biologicals to Establish Plasma

Fractionation Facility II-25

Cangene Acquires US Commercialization Rights for HepaGam B®

from Apotex II-26

7. FOCUS ON SELECT PLAYERS II-27

Baxter International Inc. (US) II-27

Beijing Tiantan Biological Products Co., Ltd (China) II-27

Bharat Serums and Vaccines Ltd (India) II-27

Biotest AG (Germany) II-27

China Biologic Products, Inc (China) II-28

CSL Limited (Australia) II-28

Grifols, S.A (Spain) II-28

Guizhou Taibang Biological Products Co., Ltd (China) II-29

Huanlan Biological Engineering Inc. (China) II-29

Kedrion S.p.A. (Italy) II-29

LFB Group (France) II-30

Octapharma AG (Switzerland) II-30

OMRIX Biopharmaceuticals Ltd (Israel) II-30

Shanghai RAAS Blood Products Co., Ltd. (China) II-30

Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China) II-30

8. GLOBAL MARKET PERSPECTIVE II-31

Table 9: World Recent Past, Current & Future Analysis for

Intravenous Immunoglobulin by Geographic Region - US, Canada,

Europe, Asia-Pacific (excluding Japan), and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) II-31

Table 10: World Historic Review for Intravenous Immunoglobulin

by Geographic Region - US, Canada, Europe, Asia-Pacific

(excluding Japan), and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2004 through 2009 (includes corresponding Graph/Chart) II-32

Table 11: World 15-Year Perspective for Intravenous

Immunoglobulin by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Europe, Asia-Pacific (excluding

Japan), and Rest of World Markets for Years 2004, 2011 & 2018

(includes corresponding Graph/Chart) II-33

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Current and Future Analysis III-1

Overview III-1

Table 12: US Market for IVIg (2006-2008): Plasma Donation

Centers in Operation (includes corresponding Graph/Chart) III-1

Table 13: US Market for IVIg (2006-2008): Plasma Donations

(in million liters) (includes corresponding Graph/Chart) III-1

Table 14: US IVIg Market (2011): Percentage Breakdown of

Market Share for Leading Players (includes corresponding

Graph/Chart) III-2

US Blood Supply System III-2

Regulatory Approvals III-3

Product Launch III-4

Strategic Corporate Developments III-4

Key Player III-6

B.Market Analytics III-6

Table 15: US Recent Past, Current & Future Analysis for

Intravenous Immunoglobulin with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-6

Table 16: US Historic Review for Intravenous Immunoglobulin

with Annual Sales Figures in US$ Million for Years 2004

through 2009 (includes corresponding Graph/Chart) III-7

2. CANADA III-8

A.Market Analysis III-8

Current and Future Analysis III-8

Overview of the Canadian Market III-8

Product Launch III-8

Strategic Corporate Developments III-9

B.Market Analytics III-10

Table 17: Canadian Recent Past, Current & Future Analysis

for Intravenous Immunoglobulin with Annual Sales Figures in

US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) III-10

Table 18: Canadian Historic Review for Intravenous

Immunoglobulin with Annual Sales Figures in US$ Million for

Years 2004 through 2009 (includes corresponding Graph/Chart) III-11

3. EUROPE III-12

A.Market Analysis III-12

Current and Future Analysis III-12

Overview of the European Market III-12

Table 19: European Market for IVIg (2006-2008): Plasma

Donation Centers in Operation (includes corresponding

Graph/Chart) III-12

European Sub-Q IVIg Product Approvals III-12

Overview of the UK Market III-12

New Concept to Stimulate Plasma Market: Welsh Blood Service

Proposes Sale of Blood Plasma III-13

Product Launches III-13

Strategic Corporate Developments III-14

Key Players III-15

B.Market Analytics III-17

Table 20: Europe Recent Past, Current & Future Analysis for

Intravenous Immunoglobulin with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-17

Table 21: European Historic Review for Intravenous

Immunoglobulin with Annual Sales Figures in US$ Million for

Years 2004 through 2009 (includes corresponding Graph/Chart) III-18

4. ASIA-PACIFIC III-19

A.Market Analysis III-19

Current and Future Analysis III-19

Overview of Select Regional Markets III-19

China III-19

Australia III-19

Plasma Products in Australia III-20

Table 22: Australia IVIg Usage by Main Indications (% of

grams used annually) (includes corresponding Graph/Chart) III-21

Indonesia III-21

Regulatory Approval III-22

Strategic Corporate Developments III-22

Key Players III-23

B.Market Analytics III-25

Table 23: Asia-Pacific Recent Past, Current & Future

Analysis for Intravenous Immunoglobulin with Annual Sales

Figures in US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) III-25

Table 24: Asia-Pacific Historic Review for Intravenous

Immunoglobulin with Annual Sales Figures in US$ Million for

Years 2004 through 2009 (includes corresponding Graph/Chart) III-26

5. REST OF WORLD III-27

A.Market Analysis III-27

Current and Future Analysis III-27

Iran Attains Self Sufficiency in Plasma Production III-27

Strategic Corporate Development III-27

Key Player III-27

B.Market Analytics III-28

Table 25: Rest of World Recent Past, Current & Future

Analysis for Intravenous Immunoglobulin with Annual Sales

Figures in US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) III-28

Table 26: Rest of World Historic Review for Intravenous

Immunoglobulin with Annual Sales Figures in US$ Million for

Years 2004 through 2009 (includes corresponding Graph/Chart) III-29

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 26 (including Divisions/Subsidiaries - 31)

The United States (9)

Canada (1)

Europe (8)

- France (1)

- Germany (1)

- The United Kingdom (1)

- Italy (1)

- Spain (1)

- Rest of Europe (3)

Asia-Pacific (Excluding Japan) (12)

Middle-East (1)

To order this report:

Blood_Supply,_Tissue_Banking_and_Transplantation Industry: Global Intravenous Immunoglobulin (IVIg) Industry

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.